https://orcid.org/0000-0002-1713-0245
References
- Ahmad A, Patel I, Parimilakrishnan S, et al. The role of pharmacoeconomics in current Indian healthcare system. J Res Pharm Pract. 2013;2(1). DOI:10.4103/2279-042X.114081
- Nair SR. Relevance of health economics to the Indian healthcare system: a perspective. Perspect Clin Res. 2015;6(4):225.
- Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
- Prathap G. Emerging trend of pharmacoeconomics and health outcomes research in India. Curr Sci. 2018;114(6):1153.
- Nguyen HN, Ly KN, Vo QT. Assessing the quality of health economic evaluation research by CHEERS instrument: a critical literature review in Laos, Cambodia, and Myanmar. J Appl Pharm Sci. 2017;7(6):222–228.
- Prinja S, Chauhan AS, Angell B, et al. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy. 2015;13(6):595–613.
- Ramaekers BLT, Joore MA, Grutters JPC. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health [Internet]. 2013;16(5):855–862.
- Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Eff Resour Allocation. 2013;11(1):6.
- Rezapour A, Jafari A, Mirmasoudi K, et al. Quality assessment of published articles in Iranian journals related to economic evaluation in health care programs based on Drummond’s checklist: a narrative review. Iran J Med Sci. 2017;42(5):427–436.
- Ademi Z, Kim H, Zomer E, et al. Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol. 2013;75(4):944–950.
- Milne RJ. Pharmacoeconomic models in disease management. Dis Manage Health Outcomes. 1998;4(3):119–134.
- Cornago D, Bassi LL, De Compadri P, et al. Pharmacoeconomic studies in Italy: a critical review of the literature. Eur J Health Econ. 2007;8(2):89–95.
- Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? Int J Technol Assess Health Care. 2008;24(2):146.
- Jakubiak-Lasocka J, Jakubczyk M. Cost-effectiveness versus cost-utility analyses: what are the motives behind using each and how do their results differ?—A Polish example. Value Health Reg Issues. 2014;4:66–74.
- Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research. Br J Pharmacol. 2010;159:1367–1373.
- Briggs AH, O’Brien BJ. The death of cost-minimization analysis? Health Econ. 2001;10(2):179–184.
- Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs–same or different? Value Health. 2009;12(4):402–404.
- Szucs TD, Mantovani LG. The perspective of a pharmacoeconomic study: targeting for audiences. Pharmacol Res. 1997 May 1;35(5):471–475.
- World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE) [Internet]. [cited 2020 Jun 20]. Available from: https://www.who.int/choice/en/